Background: Neutropenia and its complications represent one of the principal dose-limiting toxicity issues in chemotherapeutic regimens for soft tissue sarcoma. Prophylactic granulocyte colony-stimulating factor (G-CSF) reduces the risk of febrile neutropenia (FN). The correct timing of G-CSF administration should be considered in order to optimize the prophylactic treatment. Patients and Methods: Patients (≥18 years old) affected by soft tissue sarcoma and treated with epirubicin and ifosfamide, underwent prophylactic treatment with G-CSF (lenograstim at 263 μg) from day 5 to day 9. The proportion of patients experiencing FN and G4 neutropenia was considered. Results: A total of 36 patients receiving three cycles of chemotherapy with epirubicin plus ifosfamide were treated. None developed FN; G4 neutropenia was reported in 17% of patients. No treatment delay or dose reduction was required, no antibiotic therapy was administered and no hospitalization occurred. Conclusion: Five-day lenograstim treatment is efficient as prophylaxis of FN for soft tissue sarcoma chemotherapy regimens and allows maintenance of chemotherapy dose intensity.

Badalamenti, G., Incorvaia, L., Provenzano, S., Bronte, G., Leto, G., Fulfaro, F., et al. (2013). Lenograstim in preventing chemotherapy-induced febrile neutropenia in patients with soft tissue sarcoma. ANTICANCER RESEARCH, 33, 679-684.

Lenograstim in preventing chemotherapy-induced febrile neutropenia in patients with soft tissue sarcoma

BADALAMENTI, Giuseppe;INCORVAIA, Lorena;BRONTE, Giuseppe;LETO, Gaetano;FULFARO, Fabio;PROVENZANO, Salvatore;MALTESE, Giuseppa
2013-01-01

Abstract

Background: Neutropenia and its complications represent one of the principal dose-limiting toxicity issues in chemotherapeutic regimens for soft tissue sarcoma. Prophylactic granulocyte colony-stimulating factor (G-CSF) reduces the risk of febrile neutropenia (FN). The correct timing of G-CSF administration should be considered in order to optimize the prophylactic treatment. Patients and Methods: Patients (≥18 years old) affected by soft tissue sarcoma and treated with epirubicin and ifosfamide, underwent prophylactic treatment with G-CSF (lenograstim at 263 μg) from day 5 to day 9. The proportion of patients experiencing FN and G4 neutropenia was considered. Results: A total of 36 patients receiving three cycles of chemotherapy with epirubicin plus ifosfamide were treated. None developed FN; G4 neutropenia was reported in 17% of patients. No treatment delay or dose reduction was required, no antibiotic therapy was administered and no hospitalization occurred. Conclusion: Five-day lenograstim treatment is efficient as prophylaxis of FN for soft tissue sarcoma chemotherapy regimens and allows maintenance of chemotherapy dose intensity.
2013
Settore MED/06 - Oncologia Medica
Badalamenti, G., Incorvaia, L., Provenzano, S., Bronte, G., Leto, G., Fulfaro, F., et al. (2013). Lenograstim in preventing chemotherapy-induced febrile neutropenia in patients with soft tissue sarcoma. ANTICANCER RESEARCH, 33, 679-684.
File in questo prodotto:
File Dimensione Formato  
Lenograstim AR Feb 2013.pdf

accesso aperto

Descrizione: Articolo
Dimensione 124.56 kB
Formato Adobe PDF
124.56 kB Adobe PDF Visualizza/Apri
Atti_Congresso_Roma_2010_2.pdf

Solo gestori archvio

Descrizione: atti del congresso
Dimensione 3.97 MB
Formato Adobe PDF
3.97 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
badalamenti et al..pdf

accesso aperto

Dimensione 127.77 kB
Formato Adobe PDF
127.77 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/70003
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 5
social impact